The Company excluded the following from the computation
of diluted net loss per share attributable to common stockholders for the years ended December 31, 2025 and 2024 because including them
would have had an anti-dilutive effect:
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
| | |
For the Year Ended | | |
For the Year Ended | |
| | |
December 31, | | |
December 31, | |
| | |
2025 | | |
2024 | |
| Stock options to purchase common stock outstanding | |
| 1,759,211 | | |
| 1,445,211 | |
| Warrants to purchase common stock outstanding | |
| 350,000 | | |
| 350,000 | |
| Total | |
| 2,109,211 | | |
| 1,795,211 | |
| Anti-dilutive shares | |
| 2,109,211 | | |
| 1,795,211 | |
|